Description
Description
Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its products were launched in China for the treatment of ankylosing spondylitis（AS）and rheumatoid arthritis (RA) in 2018. As of the first half of 2021, Janssen Biologics BV is the only manufacturer in the Chinese Golimumab market.
According to CRI’s market research, the sales of Golimumab in the Chinese market have had a rapid upward trend from 2018 to 2020. The annual sales revenue in 2020 is CNY6.32 million, which increased over 10 times compared to that in 2018. The CAGR of Golimumab sales in the Chinese market in 2018-2020 is 242.6%. The main reason for the rapid growth is that Golimumab was included in China’s medical insurance in 2019 and it entered the national medical insurance category B list in the field of rheumatism.
CRI analyzes that from 2021 to 2025，the sales will continue to increase due to its superior efficacy and low injection frequency. In addition, Golimumab will have a very broad market and the penetration rate of SIMPONI can be improved in the future. Therefore, the market share of Golimumab has the potential to increase, which will lead the sales volume to grow in the future.
Topics Covered:
-The impact of COVID-19 on China’s Golimumab market
– Sales value of China’s Golimumab 2016-2020
– Competitive landscape of China’s Golimumab market
– Prices of Golimumab in China
– Prices of Golimumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Golimumab market
– Prospect of China’s Golimumab market from 2021 to 2025
Table of Contents
Table of Contents
1 Relevant Concepts of Golimumab
1.1 Indications for Golimumab
1.2 Development of Golimumab in China
1.3 Governmental Approval of Golimumab in China
1.4 The Impact of COVID-19 on Golimumab sales in China
2 Sales of Golimumab in China, 2018-2020
2.1 Sales Value of Golimumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2 Sales Volume of Golimumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Golimumab by Dosage Form in China, 2018-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Golimumab Manufacturers in China, 2018-2020
3.1 Analysis of Market Share of Major Golimumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Janssen Biologics BV
3.2.1 Enterprise Profile
3.2.2 Sales of SIMPONI (Janssen Biologics BV’s Golimumab) in China
4 Prices of Golimumab for Different Manufacturers in China, 2020-2021
4.1 Janssen Biologics BV (SIMPONI)
5 Prospect of Chinese Golimumab Market, 2021-2025
5.1 Influential Factors of Chinese Golimumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Golimumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Golimumab Injection Registration in China
Chart Sales Value of Golimumab Injection over the World
Chart Sales Value of Golimumab Injection in China, 2018-2020
Chart Sales Value of Golimumab Injection in China by Regions, 2018-2020
Chart Sales Volume of Golimumab Injection in China, 2018-2020
Chart Sales Volume of Golimumab Injection in China by Regions, 2018-2020
Chart Market Share by Sales Value of Top Golimumab Manufacturers in China, 2018-2020
Chart Sales Value and Volume of SIMPONI in China, 2018-2020
Chart Referential Prices of SIMPONI in China by regions, 2020-2021
Chart Forecast on Sales Value of Golimumab in China, 2021-2025
Chart Forecast on Sales Volume of Golimumab in China, 2021-2025
